New radioactive therapy targets Hard-to-Treat cancers
NCT ID NCT07232407
First seen Nov 18, 2025 · Last updated Jun 11, 2026 · Updated 23 times
Summary
This early-phase study tests a new radioactive drug called Lutetium BL-ARC001 in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it helps shrink tumors. Participants must have tumors that cannot be removed by surgery or have spread, and be in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.